A new analysis would show a reduction in the relative mortality risk by 62 percent, as the U.S. pharmaceutical company Gilead announced on Friday. Remdesivir is the only one in the EU approved drug for the specific treatment of Covid-19.
Thus, the mortality rate was higher in the standard therapy on day 14 after the start of treatment of hard-to Covid-19 patients at 12.5 percent. Patients were treated additionally with Remdesivir, died only 7.6 percent. Taking into account these Figures, and other patient-related factors of Gilead, the 62 percent reduced risk of death due to the drug. Scary moment for Prince Charles: supermarket employee flips in front of the heir to the throne to PCP scary moment for Prince Charles: supermarket employee flips in front of the heir to the throne toter/dpa Updated Date: 10 July 2020, 20:26